Keith W. Brown
Bristol, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
The epithelial splicing regulator ESRP2 is epigenetically repressed by DNA hypermethylation in Wilms tumour and acts as a tumour suppressor.
Journal: Molecular oncology
Published: June 07, 2021
Epigenetic deregulation of GATA3 in neuroblastoma is associated with increased GATA3 protein expression and with poor outcomes.
Journal: Scientific reports
Published: June 12, 2019
Genome-wide DNA methylation analysis identifies MEGF10 as a novel epigenetically repressed candidate tumor suppressor gene in neuroblastoma.
Journal: Molecular carcinogenesis
Published: July 29, 2016
Protein arginine methyltransferase 5 is a key regulator of the MYCN oncoprotein in neuroblastoma cells.
Journal: Molecular oncology
Published: September 19, 2014
Control of epigenetic states by WT1 via regulation of de novo DNA methyltransferase 3A.
Journal: Human molecular genetics
Published: October 09, 2012
MYCN is recruited to the RASSF1A promoter but is not critical for DNA hypermethylation in neuroblastoma.
Journal: Molecular carcinogenesis
Published: August 10, 2012
Insulin-like growth factor binding protein-3 (IGFBP-3) plays a role in the anti-tumorigenic effects of 5-Aza-2'-deoxycytidine (AZA) in breast cancer cells.
Journal: Experimental cell research
Published: July 27, 2012
Characterization of 17.94, a novel anaplastic Wilms' tumor cell line.
Journal: Cancer genetics
Published: November 25, 2011
DNA demethylation increases sensitivity of neuroblastoma cells to chemotherapeutic drugs.
Journal: Biochemical pharmacology
Published: November 18, 2011
Frequency and timing of loss of imprinting at 11p13 and 11p15 in Wilms' tumor development.
Journal: Molecular cancer research : MCR
Published: July 23, 2008
Showing 1-10 of 10
Last Updated: 09/26/2026